Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

Leena Gandhi,Pasi A. Jänne,Mateusz Opyrchal,Suresh S. Ramalingam,Igor I. Rybkin,Navid Hafez,Luis E. Raez,Dmitry I. Gabrilovich,Fang Wang,Peter Ordentlich,Susan Brouwer,Serap Sankoh,Emmett V. Schmidt,Michael L. Meyers,Matthew D. Hellmann

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

2018

Leena Gandhi
Pasi A. Jänne
Mateusz Opyrchal
Suresh S. Ramalingam
Igor I. Rybkin
Navid Hafez
Luis E. Raez
Dmitry I. Gabrilovich
Fang Wang
Peter Ordentlich
Susan Brouwer
Serap Sankoh
Emmett V. Schmidt
Michael L. Meyers
Matthew D. Hellmann

9036Background: Treatment options are limited in pts who progress on anti-PD-(L)1 therapy. HDAC inhibitors have the potential to modulate myeloid-derived suppressor cell (MDSC) function and may syn...

Keywords:

non-small cell lung cancer (NSCLC)
Suppressor
Cell
Entinostat
Cancer research
Pathology
Pembrolizumab
Medicine
previously treated
suppressor cell
in patient
Oncology
Internal medicine
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations